Current drug delivery

Development and Testing of Brain-Targeted Neuroactive Drug Carried by Chitosan Nanoparticles Through the Nose

Updated

Abstract

The optimized formulation RIS-CH-LNPopt has a particle size of 132.7 nm and a drug loading of 7.6%.

  • RIS-CH-LNPopt demonstrates an 80.7% drug release rate.
  • Ex-vivo permeation studies indicate a 2.32 fold enhancement in absorption compared to RIS-SUS.
  • In-vivo studies reveal greater bioefficacy for RIS-CH-LNPopt compared to RIS-SUS via both intranasal and intravenous routes.
  • The pharmacokinetic analysis shows a higher brain/plasma ratio for RIS-CH-LNPs at all time points compared to RIS-SUS.
  • The results suggest a direct nose-to-brain delivery pathway for the drug using nasal administration.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free